Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Charles Saperstein

Gastroenterology Mesa, AZ Medical Doctor

NPI 1780789826 CMS profile 35266

3048 E Baseline Rd, Suite 105, Mesa, AZ 85204

Open in the dashboard

General payments

$24,800

613 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$43,475

4 holdings reported · through program year 2024

Through program year 2024, Charles Saperstein of Mesa, AZ is reported in the CMS Open Payments database as having received $24,800 across 613 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $43,475 across 4 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $54 2
2023 General $1,675 79
2022 General $2,826 170
2021 General $2,497 147
2020 General $5,734 113
2019 General $12,014 102
2024 Ownership $20,451 1
2023 Ownership $20,451 1
2022 Ownership $1,285 1
2021 Ownership $1,287 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Saperstein
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Charles Saperstein were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Charles Saperstein Gastroenterology median Middle half National median
2019 $12,014 $417 $126–$1,100 $163
2020 $5,734 $224 $74–$624 $114
2021 $2,497 $352 $106–$1,054 $132
2022 $2,826 $448 $129–$1,270 $149
2023 $1,675 $533 $150–$1,390 $160
2024 $54 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $13,908 136 payments
  2. Allergan Inc. $4,666 30 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,216 121 payments
  4. Janssen Biotech, Inc. $787 45 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $710 27 payments
  6. Alfasigma USA, Inc. $648 90 payments
  7. Merck Sharp & Dohme Corporation $502 26 payments
  8. Pfizer Inc. $466 29 payments
  9. Celgene Corporation $274 19 payments
  10. Gilead Sciences, Inc. $255 11 payments
  11. Other $1,367 79 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13,294 12 payments
  2. Food and Beverage $9,697 589 payments
  3. Travel and Lodging $1,710 11 payments
  4. Education $99 1 payment
Products named General payments · program years 2019–2024
  1. HUMIRA $9,723 64 payments
  2. LINZESS $4,952 44 payments
  3. VIBERZI $1,371 12 payments
  4. XIFAXAN $910 84 payments
  5. STELARA $773 44 payments
  6. RINVOQ $757 29 payments
  7. DIFICID $502 26 payments
  8. XELJANZ $449 28 payments
  9. ZEPOSIA $379 20 payments
  10. SKYRIZI $371 9 payments
  11. Other $4,457 302 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

30

Median for Internal Medicine: 777

Drug cost

$453

Median for Internal Medicine: $73,373

Branded share of claims

0%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dicyclomine Hcl Generic 11 $278
Omeprazole Generic 19 $174

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RENFLEXIS
  • Organon LLC $14
$14 — —
HADLIMA
  • Organon LLC $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

613 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record